ANIP Stock — ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (ANIP)

Updated October 16, 2026.

ANIP is a Stock. Total return is -75.8% over the past 25.2 years, 996.0 points behind SPY at 920.2%.

ANI Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets branded and generic pharmaceutical products, including injectables, softgel capsules, oral solids, and specialized products like ILUVIEN and YUTIQ for ophthalmic use. The company supplies its products to wholesalers, specialty pharmacies, retail chains, hospitals, and healthcare providers across the United States and internationally. ANI does not currently have an established distribution program.

ANIP performance versus SPY

Price and return data through 2026-10-16.

Total return is -75.8% over the past 25.2 years, 996.0 points behind SPY at 920.2%. Over the past year its total return — price change plus distributions reinvested — is -21.4%. Its deepest 1-year drawdown was 26.4%.

ANIP key facts

Asset type

Stock

Asset class

Equity

Inception date

07/24/2001

Distribution frequency

None

Last close

$72.29 (as of 2026-10-16)

Market cap

$1,659,741,388

Average volume

333921.0

Beta

0.495

Payout ratio

0.0%

P/E ratio

15.65

Forward P/E

7.1174

EPS

$4.62

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ANIP risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 26.4%.

Who may consider ANIP — and who may not

It is a weaker fit for investors who need monthly cash flow (ANIP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ANIP

• All tickers starting with A

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions